Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 0.60 |
| ▸ | PRKCG | P05129 | 5/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.60 |
| ▸ | PRKCB | P05771 | 4/20 | 0.60 |
| ▸ | PRKCH | P24723 | 4/20 | 0.60 |
| ▸ | PRKCI | P41743 | 4/20 | 0.60 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.60 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.60 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.60 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.60 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.60 |
| ▸ | VAV1 | P15498 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phorbol SCHEMBL15976176 | 1.00 | PRKCA (0.60) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL2329457 | 1.00 | PRKCA (0.60) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL3403135 | 1.00 | PRKCA (0.60) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL5667270 | 1.00 | PRKCA (0.60) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL12950512 | 1.00 | PRKCA (0.60) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL14937 | 1.00 | PRKCA (0.60) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL8190878 | 1.00 | PRKCA (0.60) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL23880303 | 0.99 | PRKCA (0.59) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL5310296 | 0.99 | PRKCA (0.59) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL19435231 | 0.98 | PRKCA (0.59) | PRKCAPRKCGPRKD3PRKCBPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072196-A1 | METHODS FOR CULTURING AND ASSAYING B CELL LYMPHOCYTES | BRUKER CELLULAR ANALYSIS, INC. (US) | 2025-04-03 | — | — | WO | claimed |
| US-5955501-A | DERIVED FROM PHORBOIDS OF THE DITERPENE- AND BENZOLACTAM-CLASSES. | PROCYON PHARMACEUTICALS, INC. (US) | 1999-09-21 | — | — | US | claimed |
| EP-0457295-B1 | Use of a modulator of protein phosphorylation in the treatment of amyloidosis associated with Alzheimer's disease | UNIV ROCKEFELLER (US) | 1997-04-09 | — | — | EP | claimed |
| WO-2025072196-A1 | METHODS FOR CULTURING AND ASSAYING B CELL LYMPHOCYTES | BRUKER CELLULAR ANALYSIS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-111826431-B | Biomarkers and targets for diagnosis and treatment of cardiovascular diseases and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2022-06-17 | — | — | CN | disclosed |
| CN-103230646-B | Inner ear low-frequency shear stress vibrator for treating Meniere's disease | UNIV PLA 2ND MILITARY MEDICAL | 2015-03-11 | — | — | CN | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130261137-A1 | Methods, Compounds and Compositions Relating to Activating a Latent Virus | ULC BUSINESS PLC (GB) | 2013-10-03 | — | — | US | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| CN-100500836-C | Method for culturing HCV virus in vitro | BIOMERIEUX SA INST NAT SANTE R (FR) | 2009-06-17 | — | — | CN | disclosed |
| US-20080305502-A1 | Method of Screening Baff Suppressor or Inhibitor | KOWA COMPANY, LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| WO-2007121429-A2 | METHODS AND COMPOSITIONS FOR THE SYNERGISTIC ACTIVATION OF LATENT HIV | J. DAVID GLADSTONE INSTITUTES (US) | 2007-10-25 | — | — | WO | disclosed |
| US-7261901-B2 | Vaccine and compositions for the prevention and treatment of neisserial infections | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2007-08-28 | — | — | US | disclosed |
| EP-1801231-A1 | METHOD OF SCREENING BAFF SUPPRESSOR OR INHIBITOR | Kowa Co., Ltd. (JP) | 2007-06-27 | — | — | EP | disclosed |
| CN-1662646-A | Method for culturing hvc virus in vitro | BIOMERIEUX SA (FR) | 2005-08-31 | — | — | CN | disclosed |
| US-20040253222-A1 | Vaccine and compositions for the prevention and treatment of neisserial infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-12-16 | — | — | US | disclosed |
| US-4757019-A | Culturing mixture of epidermal cells containing keratinocytes, melanocytes, langerhans cells, and fibroblast | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1988-07-12 | — | — | US | disclosed |
| US-4716179-A | Use of non-irritating or slightly irritating and/or promoting diterpene alcohol and of derivatives thereof as antineoplastic preparations | STIFTUNG DEUTCHES KREBSFORSCHUNGSZENTRUM (DE) | 1987-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | PRKCA 1563/4885PRKCG 1219/4885PRKD3 2927/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | PRKCA 1563/4885PRKCG 1219/4885PRKD3 2927/4885 |
| US-20130261137-A1 | Methods, Compounds and Compositions Relating to Activating a Latent Virus | MAP1LC3A, PML, MAP1LC3B | PRKCA 2396/4885PRKCG 2669/4885PRKD3 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.